Laporan Laba Rugi (TTM)
Laporan Laba Rugi Akso Health Group - Depositary Receipt (Common Stock) menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.
Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.
2020 09-30 |
2020 12-31 |
2021 06-30 |
2021 09-30 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2023 03-31 |
2023 06-30 |
2023 09-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
2024 09-30 |
2024 12-31 |
2025 03-31 |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 8 | -2 | 1 | 1 | 3 | 6 | 12 | 18 | 13 | 8 | 2 | 2 | 2 | 5 | 8 | 12 | 15 |
Change (%) | -124.52 | -164.24 | -46.09 | 437.24 | 72.45 | 96.76 | 49.18 | -25.15 | -41.59 | -71.19 | 4.42 | 4.24 | 125.10 | 55.58 | 37.39 | 27.22 | |
% of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
Cost Of Sales | 13 | 7 | -6 | -13 | -1 | 5 | 11 | 16 | 12 | 7 | 2 | 2 | 2 | 5 | 8 | 12 | 15 |
Change (%) | -48.39 | -198.44 | 100.00 | -90.49 | -540.24 | 99.46 | 49.86 | -26.13 | -41.45 | -70.81 | 6.29 | 5.92 | 128.41 | 56.22 | 42.06 | 29.61 | |
% of Revenue | 166.19 | -349.82 | -536.08 | -1,988.74 | -35.22 | 89.91 | 91.15 | 91.57 | 90.37 | 90.58 | 91.80 | 93.44 | 94.94 | 96.34 | 96.74 | 100.02 | 101.91 |
Gross Operating Profit | -5 | -8 | 8 | 14 | 5 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | -0 | -0 |
Change (%) | 66.62 | -190.84 | 77.03 | -65.22 | -87.14 | 72.71 | 42.10 | -14.55 | -42.83 | -74.92 | -16.44 | -19.67 | 63.01 | 38.65 | -100.99 | 10,170.92 | |
% of Revenue | -66.19 | 449.82 | 636.08 | 2,088.74 | 135.22 | 10.09 | 8.85 | 8.43 | 9.63 | 9.42 | 8.20 | 6.56 | 5.06 | 3.66 | 3.26 | -0.02 | -1.91 |
SG&A | 48 | 4 | 31 | 33 | 22 | 3 | -0 | -4 | 16 | 16 | 17 | 13 | 9 | 8 | 7 | 5 | 4 |
Change (%) | -91.61 | 669.84 | 6.72 | -33.34 | -86.11 | -110.56 | 1,046.66 | -518.95 | 3.25 | 3.14 | -23.53 | -30.76 | -9.25 | -10.20 | -24.50 | -32.44 | |
% of Revenue | 629.28 | -215.23 | 2,579.41 | 5,105.88 | 633.50 | 51.02 | -2.74 | -21.06 | 117.86 | 208.32 | 745.90 | 546.25 | 362.84 | 146.28 | 84.44 | 46.40 | 24.64 |
R&D | |||||||||||||||||
Change (%) | |||||||||||||||||
% of Revenue | |||||||||||||||||
OpEx | 61 | 11 | 25 | 20 | 21 | 8 | 10 | 12 | 27 | 23 | 19 | 15 | 11 | 13 | 15 | 17 | 19 |
Change (%) | -82.58 | 132.30 | -17.76 | 3.11 | -59.38 | 23.42 | 18.98 | 121.04 | -16.15 | -19.27 | -20.26 | -25.40 | 19.30 | 16.18 | 11.04 | 9.94 | |
% of Revenue | 795.47 | -565.05 | 2,043.33 | 3,117.14 | 598.28 | 140.94 | 88.41 | 70.51 | 208.23 | 298.90 | 837.70 | 639.69 | 457.78 | 242.61 | 181.17 | 146.43 | 126.55 |
Operating Income | -53 | -12 | -23 | -20 | -17 | -2 | 1 | 5 | -14 | -15 | -16 | -13 | -9 | -8 | -7 | -5 | -4 |
Change (%) | -76.55 | 87.71 | -16.30 | -11.28 | -85.83 | -155.71 | 279.49 | -374.71 | 7.34 | 6.84 | -23.60 | -30.90 | -10.28 | -11.45 | -21.42 | -27.26 | |
% of Revenue | -695.47 | 665.05 | -1,943.33 | -3,017.14 | -498.28 | -40.94 | 11.59 | 29.49 | -108.23 | -198.90 | -737.70 | -539.69 | -357.78 | -142.61 | -81.17 | -46.43 | -26.55 |
Interest Expense | -2 | -2 | -2 | -2 | -1 | -1 | -1 | -0 | |||||||||
Change (%) | -5.78 | -17.25 | -14.90 | -24.80 | -32.98 | -37.31 | -59.51 | ||||||||||
% of Revenue | -31.53 | 121.17 | -156.10 | -246.38 | -34.49 | -13.40 | -4.27 | -1.16 | |||||||||
Net Income | -77 | -56 | -27 | -20 | -19 | -17 | -12 | -7 | -1 | -3 | -6 | -8 | -9 | -8 | -7 | -71 | -135 |
Change (%) | -27.45 | -50.93 | -26.68 | -8.20 | -8.93 | -28.86 | -40.57 | -80.91 | 156.92 | 61.08 | 34.03 | 25.39 | -15.18 | -17.89 | 974.46 | 90.69 | |
% of Revenue | -1,012.50 | 2,996.00 | -2,288.48 | -3,112.16 | -531.80 | -280.85 | -101.54 | -40.46 | -10.32 | -45.38 | -253.73 | -325.68 | -391.78 | -147.63 | -77.92 | -609.33 | -913.38 |
Source: Capital IQ